Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31508344 | 0.82 | DHODH (0.34) | CCR5HTR2AHTR2CHTR7RPS6KB1 | |
| SCHEMBL24021370 | 0.82 | NPC1 (0.47) | IDO1 | |
| SCHEMBL21795787 | 0.82 | NPC1 (0.47) | IDO1 | |
| SCHEMBL14335923 | 0.81 | CCR5 (0.51) | CCR5HTR2ACYP2D6HTR2CKDM4E | |
| SCHEMBL22558863 | 0.81 | EPHX2 (0.43) | CYP3A4 | |
| SCHEMBL16632108 | 0.81 | EPHX2 (0.43) | CYP3A4 | |
| SCHEMBL28563087 | 0.77 | CCR5 (0.32) | CCR5HMOX1 | |
| SCHEMBL4566750 | 0.76 | HTR2A (0.55) | HTR2ACYP2D6HTR2CKDM4ECYP1A2 | |
| SCHEMBL6229667 | 0.76 | HTR2A (0.56) | HTR2ACYP2D6HTR2CKDM4ECYP1A2 | |
| SCHEMBL15536002 | 0.76 | FPR2 (0.47) | HTR2ACYP2D6HTR2CKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179391-B2 | Compound with kinase inhibitory activity and preparation method and use thereof | Zhang, Fuyao (CN) | 2021-11-23 | — | — | US | disclosed |
| EP-3620456-B1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ZHANG FUYAO (CN) | 2021-11-17 | — | — | EP | disclosed |
| CN-108794452-B | Compound with kinase inhibition activity, preparation method and application thereof | 上海时莱生物技术有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200155550-A1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2020-05-21 | — | — | US | disclosed |
| EP-3620456-A1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | Selection Bioscience LLC (CN) | 2020-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155550-A1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | CDK9, CDK7, CDK6 | CCR5 2964/4885HMOX1 4556/4885HTR2A 4665/4885 |
| US-11179391-B2 | Compound with kinase inhibitory activity and preparation method and use thereof | CDK9, CDK7, CDK6 | CCR5 2964/4885HMOX1 4556/4885HTR2A 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.